The Korean pharmaceutical industry has raised an ongoing investment rate for the R&D-to-sales according to the KPMA report.
The report indicated that the total sales of 37 listed drug companies in 2004 amounted to 5,045,400 million won, 5% (254,100 million won) of which was spent for the R&D.
The R&D investment showed an ongoing rise during the past few years from 2.86% (91 billion won...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.